Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naloxone HCl prolonged-release tablets for opioid-induced constipation
2012-004311-31Phase 3Completed
- Sponsor
- Develco Pharma
- Start
- Jan 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in opioid-induced constipation (OIC) and opioid-induced bowel dysfunction (OIBD) comparing Naloxone hydrochloride prolonged-release tablets with Placebo (2 arms). Primary endpoint: Absolute change in Bowel Function Index score at Week 12. Started Jan 2013; status: completed.
02
Drugs
naloxone
03
Conditions
opioid-induced constipation (OIC)opioid-induced bowel dysfunction (OIBD)
Beyond the preview
Go deeper on 2012-004311-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004311-31.